CD38 / CD19 / Firefly Luciferase CHO Recombinant Cell Line
Recombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein (also known as ADPRC1, Genbank accession #NM_001775) and human CD19 protein (also known as B4 or CVID3, Genbank accession #NM_001770). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD38 and CD19 were confirmed by flow cytometry.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
Name | Ordering Information |
Thaw Medium 3 | BPS Bioscience #60186 |
Growth Medium 3K | BPS Bioscience #78041 |
Materials Required for Cellular Assay
Name | Ordering Information |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
96-well tissue culture-treated white clear-bottom assay plate | |
Luminometer |
The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
The CD38 protein is a dimeric, non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes the second messengers cyclic ADP-ribose and NADP. CD38 is highly expressed by lymphoid and myeloid cells, particularly plasma cells. Increased CD38 expression on chronic lymphocytic leukemia (CLL) cells is linked to aggressive disease features and poor clinical outcome. CD38 is used as a prognostic marker for patients with CLL and multiple myeloma (MM), and is an ideal target for immunotherapy in CLL and MM.
B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkin’s Lymphoma (NHL), CLL and ALL.